Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Special report: multiple molecular testing of cancers to identify targeted therapies.

BlueCross BlueShield Association.

Technol Eval Cent Assess Program Exec Summ. 2013 Jun;28(1):1-2. No abstract available.

PMID:
23865106
2.

Special report: exome sequencing for clinical diagnosis of patients with suspected genetic disorders.

Blue Cross and Blue Shield Association.

Technol Eval Cent Assess Program Exec Summ. 2013 Aug;28(3):1-4. No abstract available.

PMID:
24066368
3.

Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2011 Nov;26(7):1-5. No abstract available.

PMID:
22724160
4.

Genetic testing for HFE gene mutations related to hereditary hemochromatosis.

[No authors listed]

Tecnologica MAP Suppl. 2001 Dec 6:20-5. No abstract available.

PMID:
11933937
5.

Multianalyte testing for the evaluation of adnexal masses.

BlueCross BlueShield Association.

Technol Eval Cent Assess Program Exec Summ. 2013 Apr;27(8):1-3. No abstract available.

PMID:
23865108
6.

Genetic testing for inherited susceptibility of colorectal cancer: part II. Hereditary nonpolyposis colorectal cancer (HNPCC).

[No authors listed]

Tecnologica MAP Suppl. 1998 Feb:10-5. No abstract available.

PMID:
10183352
7.

[Molecular targeted cancer therapy and genetic tests --chairman's introductory remarks].

Hinoda Y.

Rinsho Byori. 2012 Oct;60(10):967-8. Japanese.

PMID:
23323461
8.

Genetic testing for predisposition to inherited hypertrophic cardiomyopathy.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2010 Aug;24(11):1-5. No abstract available.

PMID:
21114064
9.

Sequencing-based tests to determine fetal down syndrome (trisomy 21) from maternal plasma DNA.

BlueCross BlueShield Association.

Technol Eval Cent Assess Program Exec Summ. 2013 Apr;27(10):1-6. No abstract available.

PMID:
23866392
10.

Genetic testing for inherited susceptibility to colorectal cancer: part I. Adenomatous polyposis coli (APC) gene mutations.

[No authors listed]

Tecnologica MAP Suppl. 1998 Feb:5-10. No abstract available.

PMID:
10183351
11.
12.

Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2010 Aug;24(13):1-3. No abstract available.

PMID:
21114065
13.

The cost-effectiveness of three new technologies to enhance Pap testing.

[No authors listed]

Tecnologica MAP Suppl. 1998 Feb:40-1. No abstract available.

PMID:
10183360
14.

Intravenous immune globulin for multiple sclerosis.

[No authors listed]

Tecnologica. 1995 May:10.

PMID:
10168292
15.

Biofeedback.

[No authors listed]

Tecnologica. 1996 Mar:7-8. No abstract available.

PMID:
10168309
16.

Off-label uses of trastuzumab.

[No authors listed]

Tecnologica MAP Suppl. 1999 Apr:22-3. No abstract available.

PMID:
10848167
17.

Chemotherapy sensitivity and resistance assays.

[No authors listed]

Tecnologica MAP Suppl. 2000 Jun:3-6. No abstract available.

PMID:
11067680
18.

Special report: screening asymptomatic women with dense breasts and normal mammograms for breast cancer.

Blue Cross Blue Shield Association; Kaiser Permanente.

Technol Eval Cent Assess Program Exec Summ. 2014 Apr;28(15):1-2. No abstract available.

PMID:
24933744
19.

Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2004 Apr;19(2):1. No abstract available.

PMID:
15314825
20.

Intravenous immune globulin for multiple sclerosis.

[No authors listed]

Tecnologica MAP Suppl. 1998 Aug:3-5. No abstract available.

PMID:
10342975

Supplemental Content

Support Center